Evidence-Based Oncology > April 2017
Evidence-Based Oncology - April 2017
April 17, 2017 – Harold D. Miller
By identifying ways to improve cancer care and then designing alternative payment models (APMs) to overcome current payment barriers, APMs can enable oncology practices to deliver better care to patients and save money for payers in a way that is financially sustainable for the practices.
April 17, 2017 – Sachin M. Apte, MD, MS, MBA
A dive into the Quality Payment Program and other healthcare reform models introduced in cancer care that healthcare providers are adjusting to as we move toward value-based care.
April 18, 2017 – Sonal Shah, PharmD, and Greg Reh
The Deloitte Center for Health Solutions recently interviewed individuals from health plans, providers, and clinical pathway developers that are participating, supporting, or evaluating oncology payment models to understand what approaches are perceived to be working, the early results, and the potential impact on innovation.
CMS Needs to Address Medicare Underfunding in 2017 Hospital Inpatient Rule for Bone Marrow Transplantation
April 18, 2017 – Jeffrey W. Chell, MD
The Be The Match Registry has seen phenomenal success with bone marrow and umbilical cord transplants. After having overcome donor availability, it is now important for CMS to create standardized reimbursement policies for the procedure.
April 19, 2017 – Brenton Fargnoli, MD; Ryan Holleran; and Michael Kolodziej, MD
The emergence of alternative payment models, as exemplified by the Oncology Care Model, is requiring oncologists to develop new solutions to meet the requirements of these programs. Technology available at the point of care offers an efficient solution to many of the most labor-intensive processes.
April 19, 2017 – Barbara McAneny, MD; Stephen S. Grubbs, MD; Walter Birch, MBA; Dan Sayam Zuckerman, MD
The American Society of Clinical Oncology has developed the Patient-Centered Oncology Payment (PCOP) model with the hope that PCOP will be accepted by CMS as an advanced alternative payment model, and become available to medical oncologists as an alternative to the Merit-based Incentive Payment System.
The Oncogenic Hepatitis C Virus and Direct-Acting Antivirals: Economic Implications for Hepatocellular Carcinoma in Medicaid Beneficiaries With Cirrhosis
April 20, 2017 – S. Mantravadi, PhD, MS, MPH
The oncogenic effects of the hepatitis C virus can impact patient outcomes for hepatocellular carcinoma (HCC) and have economic implications for medical spending. This study underscores the importance of treating patients early in the disease process for savings associated with reducing the risks of HCC.
April 20, 2017 – Joseph Alvarnas, MD
As the task of describing value delivery in cancer care seems to grow in complexity the closer that we examine it, this is essential in order to both rationally control the growth of healthcare costs and ensure that we do not undermine patient care.